Stent thrombosis and duration of dual antiplatelet therapy

Area of Science:

• Cardiology
• Interventional Cardiology
• Biomaterials Science

Background:

• Stent thrombosis (ST) is a rare but severe complication post-coronary stenting, leading to myocardial infarction and death.
• While early ST rates are similar between drug-eluting stents (DES) and bare-metal stents (BMS), long-term adverse outcomes with DES have been reported.
• Delayed endothelialization, inflammation, and hypersensitivity reactions are characteristic of DES, potentially increasing ST risk.

Purpose of the Study:

• To review the current understanding of stent thrombosis in relation to stent type and dual antiplatelet therapy (DAT).
• To highlight the ongoing debate and inconclusive evidence regarding the optimal duration of DAT following DES implantation.
• To emphasize the need for further research into newer DES generations, antiplatelet response variability, and novel therapies.

Main Methods:

• Review of existing literature comparing early and late stent thrombosis rates between DES and BMS.
• Analysis of factors contributing to delayed stent coverage and inflammation with DES.
• Examination of current recommendations and ongoing research on dual antiplatelet therapy (DAT) duration.

Main Results:

• No significant difference in early stent thrombosis (ST) between DES and BMS.
• Potential for increased long-term ST risk with DES due to delayed endothelial coverage and inflammatory responses.
• Current recommendations suggest 6-12 months of DAT for DES, but optimal duration remains inconclusive.

Conclusions:

• Further analysis of treatment strategies is required for stent thrombosis prevention.
• Understanding the impact of newer DES generations and individual antiplatelet response is crucial.
• More data on novel therapeutic agents and optimal DAT duration are needed to refine clinical practice.